12:00 AM
Nov 17, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Arenegyr: Preliminary Phase II data

In an open-label, Italian Phase II trial (Study NGR010) of Arenegyr in 39 patients, median overall survival is >12 months and has not been reached....

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >